Investigation and management of the monoclonal gammopathy of undetermined significance
Simon Stern, Satarupa Chaudhuri, Mark T. Drayson, Sarah Henshaw, Kamaraj Karunanithi, Fenella Willis, the Haemato‐Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum
Abstract
This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
Topics & Concepts
Monoclonal gammopathy of undetermined significanceMonoclonal gammopathyMedicineRisk stratificationIntensive care medicineClinical significanceMultiple myelomaMonoclonalMonoclonal antibodyPathologyInternal medicineImmunologyAntibodyMultiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, OutcomesChronic Lymphocytic Leukemia Research